Fig 1: ITGA7 knockdown regulates common CSC markers in CAL-27 cells and HSC-4 cells. (A) CD24, (B) CD44 and (C) CD133 mRNA expression levels in ITGA7(-) and NC CAL-27 cells. (D) Protein expression levels of CSC markers in ITGA7(-) and NC CAL-27 cells. (E) CD24, (F) CD44 and (G) CD133 mRNA expression levels in ITGA7(-) and NC HSC-4 cells. (H) Protein expression levels of CSC markers in ITGA7(-) and NC HSC-4 cells. *P<0.05, **P<0.01 and ***P<0.001. ITGA7, integrin a7; NC, negative control; CSC, cancer stemness cell.
Fig 2: CCK‐8, AV/PI, and Matrigel invasion assays. ITGA7 mRNA expression was decreased in ITGA7 knockdown group compared to control group (A). ITGA7 protein expression was lower in ITGA7 knockdown group compared to control group (B). Cell viability was reduced in ITGA7 knockdown group compared to control group at 48 h and 72 h (C). Cell apoptosis rate was increased in ITGA7 knockdown group compared to control group (D, E). Cell count using Matrigel invasion assay was reduced in ITGA7 knockdown group compared to control group (F, G). Comparison between two groups was determined by t test. P < .05 was considered significant. *P < .05; **P < .01; ***P < .001. CCK‐8, Cell Counting Kit‐8; AV/PI, Annexin V/ propidium iodide; ITGA7, integrin α7
Fig 3: ITGA7 acts as a potential marker of CSCs in CAL-27 and HSC-4 cell lines. (A) CCK-8 assay of untreated and cisplatin treated R CAL-27 cells. (B) Representative photomicrograph of a sphere (magnification, x200) after lentivirus transfection in R-CAL-27 cells. (C) Number of spheres/1,000 cells in R CAL-27 and parental CAL-27 cells. (D) CD24, (E) CD44, (F) CD133 and (G) ITGA7 mRNA expression levels in CAL-27 CSCs and CAL-27 parental cells. (H) Protein expression levels of CSC markers in CAL-27 CSCs and CAL-27 parental cells. (I) CCK 8 assay of untreated and cisplatin treated R HSC 4 cells. (J) Representative photomicrograph of a sphere (magnification, ×200) after lentivirus transfection in R-HSC-4 cells. (K) Number of spheres/1,000 cells in R HSC-4 and parental HSC-4 cells. (L) CD24, (M) CD44, (N) CD133 and (O) ITGA7 mRNA expression levels in HSC-4 CSCs and HSC-4 parental cells. (P) Protein expression levels of CSC markers in HSC-4 CSCs and HSC-4 parental cells. **P<0.01 and ***P<0.001. ITGA7, integrin a7; CSC, cancer stemness cell; CCK-8, Cell Counting Kit-8; R-, resistant; OD, optical density; NS, not significant.
Fig 4: ITGA7 protein and mRNA expression in tongue squamous cell carcinoma and adjacent normal tissues. (A) Representative images of ITGA7 high or low protein expression staining (magnification, ×200). (B) Quantification of tissues with high ITGA7 protein expression. (C) mRNA expression levels of ITGA7 in tumor and paired adjacent tissues. ITGA7, integrin a7.
Fig 5: ITGA7 knockdown inhibits cell proliferation and promotes cell apoptosis in CAL-27 and HSC-4 cells. (A) Cell proliferation in ITGA7(-) and NC groups of CAL-27 cells was measured by CCK-8 assay. (B) Quantification and (C) representative plots from flow cytometry apoptosis analysis in CAL-27 cells. (D) Protein expression levels of apoptosis related markers were detected by western blotting in CAL-27 cells. (E) Cell proliferation in ITGA7() and NC groups of HSC-4 cells was measured by CCK-8 assay. (F) Quantification and (G) representative plots from flow cytometry apoptosis analysis in HSC-4 cells. (H) Protein expression levels of apoptosis-related markers were detected by western blotting in HSC-4 cells. *P<0.05 and **P<0.01. ITGA7, integrin a7; NC, negative control; CCK-8, Cell Counting Kit 8; OD, optical density; PI, propidium iodide.
Supplier Page from Abcam for Anti-ITGA7 antibody